Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
9 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07361029 | CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia(CD19 CART CELL) | recruiting | Phase 1 | 24 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06326697 | Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 32 | Hikma Pharmaceuticals LLCINDUSTRY | 1 |
| Sep 26, 2025 |
| clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT06044142 | Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment | completed | Phase 1 | 90 | Riyadh Elm UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT02628132 | Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients | completed | Phase 1 / Phase 2 | 22 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04138342 | Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer | unknown | Phase 1 | 30 | Al-Azhar UniversityOTHER | 2 | Oct 24, 2019 | clinicaltrials |
| NCT03774680 | Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer | unknown | Phase 1 | 30 | Ahmed A. H. AbdellatifOTHER | 2 | Oct 10, 2019 | clinicaltrials |
| NCT03629847 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | unknown | Phase 1 / Phase 2 | 30 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT02919371 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | unknown | Phase 1 / Phase 2 | 77 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 10, 2018 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials